Discontinuation of phenytoin, carbamazepine, and valproate in patients with active epilepsy.
The effects of discontinuing individual antiepileptic drugs (AEDs) in patients with active epilepsy who are receiving combination therapy have not been studied systematically. We report a double-blind, prospective study of discontinuation of phenytoin (PHT), carbamazepine (CBZ), and valproate (VPA) in 70 patients with chronic active epilepsy. Each drug discontinuation was randomized to one of two relatively fast rates of reduction, and a control group of 25 patients continued with stable therapy. Patients who had CBZ removed had a significant increase in seizures that was maintained for 4 weeks after the end of drug reduction, and 10 of these 23 patients had to restart therapy with CBZ. There was no significant change in seizure numbers in the other groups. Two patients discontinued from VPA had to restart the drug; none had to restart PHT. The optimal rates of reduction of CBZ remain uncertain. There was no evidence for a clinically or temporally distinct burst of "discontinuation seizures" in any group. Any marked increase in seizures always resolved on reintroduction of the discontinued drug.
Duncan
J S
JS
INSEG (Institute of Neurology, National Society for Epilepsy Research Group), London, England.
Shorvon
S D
SD
Trimble
M R
MR
D002220:Carbamazepine / Q000008:administration & dosage* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004828:Epilepsies, Partial / Q000188:drug therapy; D004827:Epilepsy / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D010672:Phenytoin / Q000008:administration & dosage* / Q000627:therapeutic use; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology; D014635:Valproic Acid / Q000008:administration & dosage* / Q000627:therapeutic use
D002220:Carbamazepine; D014635:Valproic Acid; D010672:Phenytoin